Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study
Int. Journal of Clinical Pharmacology and Therapeutics · 01.05.2026 · 64 (05) · 250-258
DOI: 10.5414/cp204899 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.05.2026. Verfasst von Satoru Matsunuma und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Proton Pump Inhibitors, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Matsunuma, S., Hirota, Y., & Yoshimoto, K. (2026). Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study. Int. Journal of Clinical Pharmacology and Therapeutics, 64(05), 250-258. https://doi.org/10.5414/cp204899
Vancouver
Matsunuma S, Hirota Y, Yoshimoto K. Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(05):250-258. doi:10.5414/cp204899
BibTeX
@article{Matsunuma2026,
author = {Matsunuma, Satoru and Hirota, Yusuke and Yoshimoto, Koichi},
title = {Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {05},
pages = {250--258},
doi = {10.5414/cp204899}
}
EUVIMED